Paper Details

  1. Home
  2. Paper Details

Lesinurad, a Selective Uric Acid Reabsorption Inhibitor, in Combination With Febuxostat in Patients With Tophaceous Gout: Findings of a Phase III Clinical Trial.

Author: AdlerScott, BaumgartnerScott, BhaktaNihar, DalbethNicola, FungMaple, JonesGraeme, KhannaDinesh, KopickoJeff, Perez-RuizFernando, StorgardChris, TerkeltaubRobert

Clinical Trial, Phase IIIA Phase III trial is a trial that further rigorously verifies the efficacy and safety of a new drug or treatment, whose efficacy and safety have been confirmed in a Phase II trial, in a large number of patients, and evaluates whether it is superior to existing treatments.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

This study investigated the efficacy and safety of lesinurad in combination with febuxostat in a 12-month phase III trial in patients with tophaceous gout. Treatment with lesinurad in combination with febuxostat demonstrated superior lowering of serum UA levels as compared with febuxostat alone, with clinically relevant added effects on tophi and an acceptable safety profile with lesinurad 200 mg.
Paper Details　
Original Abstract of the Article :
OBJECTIVE: To investigate the efficacy and safety of lesinurad in combination with febuxostat in a 12-month phase III trial in patients with tophaceous gout. METHODS: Patients with serum urate (UA) ≥8.0 mg/dl (≥6.0 mg/dl with urate-lowering therapy) and ≥1 measurable target tophus were given febuxo...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5601200/

データ提供：米国国立医学図書館（NLM）

A Powerful Duo for Tophaceous Gout: Lesinurad and Febuxostat

Gout, a painful condition caused by high uric acid levels in the body, can feel like walking through a desert of sharp stones. This study investigates the effectiveness of a combination therapy, lesinurad and febuxostat, for patients with tophaceous gout, a more severe form of the disease. The researchers are searching for a way to pave a smoother path through the desert, alleviating the pain and discomfort of gout.

The study found that adding lesinurad to febuxostat significantly lowered uric acid levels, a key factor in managing gout. It's like finding a hidden trail that leads to a source of water, helping to quench the thirst of the desert traveler.

Smoothing the Path: Combining Therapies for Tophaceous Gout

This research provides encouraging news for patients with tophaceous gout. It's like finding a hidden oasis that offers a haven from the harsh desert conditions. The study demonstrates the effectiveness of combining lesinurad and febuxostat in lowering uric acid levels and improving gout symptoms. This finding opens up a new avenue for managing this debilitating condition.

The study also highlights the importance of careful monitoring for potential side effects, like a wise traveler who keeps an eye out for hidden dangers in the desert. This research offers a glimmer of hope for patients with tophaceous gout, providing a potential path to a more comfortable and fulfilling life.

Dr.Camel's Conclusion

Combining lesinurad and febuxostat offers a promising approach to managing tophaceous gout. This therapy is like finding a hidden spring of relief in the desert of gout, offering a smoother path to a more comfortable life.

Date :
  1. Date Completed 2017-09-21
  2. Date Revised 2022-04-09
Further Info :

Pubmed ID

28597604

DOI: Digital Object Identifier

PMC5601200

Related Literature

Article Analysis
・Effects of lesinurad
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.